A Novel Method to Estimate Levels of Receptors Using an Allosteric Modulator: Focus on Muscarinic M1 Receptor

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2023 Jul 18

PMID 37464158

Authors

Geoffrey Pavey

Megan Snelleksz

Brian Dean

Affiliations

Soon will be listed here.

Abstract

This chapter outlines some of the general principles that need to be considered when developing a radioligand binding assay to measure the affinity and density of radioligand binding to a receptor in tissue or on cells. In addition it describes an innovative step forward in using radioligand binding assays to measure levels of muscarinic M1 receptors in human postmortem CNS, using both membrane binding and in situ radioligand binding. These examples show how, using receptor-specific allosteric modulators, it is possible to gain an estimate of the density of a single receptor using a radioligand that is not totally specific to the target site of interest. Given there is a growing understanding that there are problems with antibodies not showing specificity to their supposed target protein, well-characterized radioligand binding techniques still provide an important tool when studying receptor density in tissues and cells.

References

Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E . Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry. 2002; 7(10):1083-91. DOI: 10.1038/sj.mp.4001199. View

Mahmood T, Yang P . Western blot: technique, theory, and trouble shooting. N Am J Med Sci. 2012; 4(9):429-34. PMC: 3456489. DOI: 10.4103/1947-2714.100998. View

Koussounadis A, Langdon S, Um I, Harrison D, Smith V . Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. Sci Rep. 2015; 5:10775. PMC: 4459080. DOI: 10.1038/srep10775. View

Ghosh R, Gilda J, Gomes A . The necessity of and strategies for improving confidence in the accuracy of western blots. Expert Rev Proteomics. 2014; 11(5):549-60. PMC: 4791038. DOI: 10.1586/14789450.2014.939635. View

Hansen E, Knudsen J . Limitations in the use of the enzyme-linked immunosorbent assay (ELISA) for identification and quantification of thermogenin. J Immunol Methods. 1985; 77(2):297-304. DOI: 10.1016/0022-1759(85)90043-2. View

Scarr E, Dean B . Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?. J Neurochem. 2008; 107(5):1188-95. DOI: 10.1111/j.1471-4159.2008.05711.x. View

Dean B, Crook J, Opeskin K, Hill C, Keks N, Copolov D . The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry. 1996; 1(1):54-8. View

Dean B, Hayes W . Decreased frontal cortical serotonin2A receptors in schizophrenia. Schizophr Res. 1996; 21(3):133-9. DOI: 10.1016/0920-9964(96)00034-5. View

Sekiguchi H, Pavey G, Dean B . Altered levels of dopamine transporter in the frontal pole and dorsal striatum in schizophrenia. NPJ Schizophr. 2019; 5(1):20. PMC: 6888821. DOI: 10.1038/s41537-019-0087-7. View

10.

Dean B, Pavey G, Thomas D, Scarr E . Cortical serotonin7, 1D and 1F receptors: effects of schizophrenia, suicide and antipsychotic drug treatment. Schizophr Res. 2006; 88(1-3):265-74. DOI: 10.1016/j.schres.2006.07.003. View

11.

Dean B, Crossland N, Boer S, Scarr E . Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia. Schizophr Res. 2008; 104(1-3):185-97. DOI: 10.1016/j.schres.2008.06.011. View

12.

Dean B, Pavey G, Opeskin K . [3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects. Neuropharmacology. 1997; 36(6):779-86. DOI: 10.1016/s0028-3908(97)00067-1. View

13.

Dean B, Soulby A, Evin G, Scarr E . Levels of [(3)H]pirenzepine binding in Brodmann's area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1. Schizophr Res. 2008; 106(2-3):229-36. DOI: 10.1016/j.schres.2008.08.003. View

14.

Crook J, Tomaskovic-Crook E, Copolov D, Dean B . Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry. 2001; 158(6):918-25. DOI: 10.1176/appi.ajp.158.6.918. View

15.

Dean B, Opeskin K, Pavey G, Naylor L, Hill C, Keks N . [3H]paroxetine binding is altered in the hippocampus but not the frontal cortex or caudate nucleus from subjects with schizophrenia. J Neurochem. 1995; 64(3):1197-202. DOI: 10.1046/j.1471-4159.1995.64031197.x. View

16.

Ma L, Seager M, Seager M, Wittmann M, Jacobson M, Bickel D . Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U S A. 2009; 106(37):15950-5. PMC: 2732705. DOI: 10.1073/pnas.0900903106. View

17.

Shirey J, Brady A, Jones P, Davis A, Bridges T, Kennedy J . A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci. 2009; 29(45):14271-86. PMC: 2811323. DOI: 10.1523/JNEUROSCI.3930-09.2009. View

18.

Dean B, Hopper S, Conn P, Scarr E . Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations. Neuropsychopharmacology. 2015; 41(6):1620-8. PMC: 4832025. DOI: 10.1038/npp.2015.330. View

19.

Hopper S, Pavey G, Gogos A, Dean B . Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia. Int J Neuropsychopharmacol. 2019; 22(10):640-650. PMC: 6822142. DOI: 10.1093/ijnp/pyz045. View

20.

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View